Scholarlink

Purpose <p>To investigate the prognostic value of the CALLY index for colorectal cancer.</p> Methods <p>The subjects if this retrospective analysis were patients who underwent laparoscopic or robot-assisted surgery for pathological stage II–III colorectal cancer between 2009 and 2023 at a single center. The relationship between the CALLY index and prognosis was compared with the prognostic nutritional index and the modified Glasgow prognostic score, and its association with clinicopathological features and perioperative treatment was assessed. Subgroup analyses were performed based on pathological stage. A meta-analysis of published studies was performed to establish a harmonized cutoff value for the CALLY index.</p> Results <p>A total of 338 patients were enrolled. The optimal CALLY cutoff was 3.67. A CALLY index of &lt; 3.67 was an independent predictor of poor outcomes in multivariate Cox regression analyses. The 3-year-overall survival rates were 97.3% and 88.3% in the high- and low-CALLY groups, respectively (<i>P</i> = 0.005). The subgroup analyses revealed that patients with stage III colorectal cancer and a low-CALLY index had poorer survival and were less likely to receive oxaliplatin-based adjuvant chemotherapy. The meta-analysis yielded a pooled cutoff value of 3.18 (95% CI, 1.48–4.88).</p> Conclusions <p>The CALLY index outperforms existing biomarkers and is valuable for prognostic stratification and treatment decision-making in patients with resectable colorectal cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The CALLY index as a predictive biomarker for the prognosis and treatment outcomes of colorectal cancer

  • 期刊论文

  • 发表日期：

    2026年2月11日

查看全文
  • Chihiro Ishizuka,
  • Ken Imaizumi,
  • Nobuki Ichikawa,
  • Tadashi Yoshida,
  • Yosuke Ohno,
  • Kengo Shibata,
  • Akinobu Taketomi

摘要

Purpose

To investigate the prognostic value of the CALLY index for colorectal cancer.

Methods

The subjects if this retrospective analysis were patients who underwent laparoscopic or robot-assisted surgery for pathological stage II–III colorectal cancer between 2009 and 2023 at a single center. The relationship between the CALLY index and prognosis was compared with the prognostic nutritional index and the modified Glasgow prognostic score, and its association with clinicopathological features and perioperative treatment was assessed. Subgroup analyses were performed based on pathological stage. A meta-analysis of published studies was performed to establish a harmonized cutoff value for the CALLY index.

Results

A total of 338 patients were enrolled. The optimal CALLY cutoff was 3.67. A CALLY index of < 3.67 was an independent predictor of poor outcomes in multivariate Cox regression analyses. The 3-year-overall survival rates were 97.3% and 88.3% in the high- and low-CALLY groups, respectively (P = 0.005). The subgroup analyses revealed that patients with stage III colorectal cancer and a low-CALLY index had poorer survival and were less likely to receive oxaliplatin-based adjuvant chemotherapy. The meta-analysis yielded a pooled cutoff value of 3.18 (95% CI, 1.48–4.88).

Conclusions

The CALLY index outperforms existing biomarkers and is valuable for prognostic stratification and treatment decision-making in patients with resectable colorectal cancer.